Kenneth Jacobson

Dr. Jacobson is Chief of the Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases

[Kenneth Jacobson @KAJacobson]

@michael_krashes Congratulations!

[Astrocyte Pharmaceuticals @AstrocytePharma]

Very exciting to have this new review out today by Ted Liston, who pioneered AST-004's development over this past decade! It has indeed been a remarkable journey! Thanks to Jim Lechleiter, @KAJacobson, and everyone across the @AstrocytePharma team! https://t.co/RseoFtf5Rc

[Astrocyte Pharmaceuticals @AstrocytePharma]

Thanks to @BioTuesdays for the deep dive on our work at @AstrocytePharma. 2026 is a pivotal year: Phase 2 trials are enrolling, our Series B is underway, and we’re moving closer to that much-needed neuroprotective therapy for #TBI and #stroke patients! https://t.co/o2Nsb2j95i

[Communications Biology @CommsBio]

UDP-glucose and MRS2905 agonist-bound states of the purinergic P2Y14 receptor: Communications Biology, Published online: 21 November 2025; doi:10.1038/s42003-025-09174-6The authors cracked P2Y14’s “sweet tooth”: structures bound to UDP-glucose and… https://t.co/aeAkTqNd5M

[Astrocyte Pharmaceuticals @AstrocytePharma]

Footy star reveals concussion toll: 'I haven't slept unaided in years' https://t.co/PICE6y0gxD via @MailSport Astrocyte's new #STARFAST clinical trial is now treating concussed players in the Adelaide Footy League with AST-004 to see if we can limit these debilitating effects.

[Astrocyte Pharmaceuticals @AstrocytePharma]

Great story by 7NEWS Adelaide covering @AstrocytePharma STARFAST Phase 2 clinical trial!! https://t.co/IRTUxlAXTO

[Astrocyte Pharmaceuticals @AstrocytePharma]

🚀 More great news! @AstrocytePharma is honored to receive a $3M grant from the NIH to further advance the oral formulation of AST-004 toward an IND and the clinic! #concussion #TBI https://t.co/l1cilsLxMY

[Kenneth Jacobson @KAJacobson]

Carolyn Bertozzi delivered an amazing Margaret Pittman lecture today at NIH, & succeeded to explain complicated bioorthogonal chemistry to the broader scientific audience.

[Astrocyte Pharmaceuticals @AstrocytePharma]

Astrocytes are stepping into the spotlight. 🌟
A trio of new Science papers reveals just how central these cells are to brain function—and why they may be the key to recovery after injury. Huge implications for TBI and stroke.
https://t.co/2Lwpnpsddb

[Eric Topol @EricTopol]

Astrocytes have long been conceived as passive support player cells in the brain. But today @ScienceMagazine (via 3 reports) they got a big upgrade for their active role in neuromodulation and control of brain function
https://t.co/LHwIwNhY4k

[Astrocyte Pharmaceuticals @AstrocytePharma]

A great week at the #TBIconference—Astrocyte was thrilled to be part of the scientific exchange and momentum driving new treatments forward. Dr. Korinek presented updates on the cerebroprotectant AST-004 advancing to Phase 2 clinical trials. #concussion #TBI #BrainHealth

[Kenneth Jacobson @KAJacobson]

@AstrocytePharma @StrokeAHA_ASA Result of our collaboration (CRADA) with Astrocyte, adenosine receptor agonist for cerebroprotection!

[Astrocyte Pharmaceuticals @AstrocytePharma]

Summary of Astrocyte's Phase 1A clinical trial of AST-004 featured this month in @StrokeAHA_ASA's Article Commentary. For the Phase 1B study that also showed high safety and tolerability of extending dosing, the manuscript is in preparation - stay tuned! https://t.co/r3CM3mCXI6

[Kenneth Jacobson @KAJacobson]

https://t.co/3z68rKrg6R
Photoswitchable A3 adenosine receptor agonist @IRPatNIH

[PhysOrgChem@MU @PhysOrgChem_MU]

Beautiful excursion into the history and importance of Photoremovable Protecting Groups: https://t.co/PUvVuMAHFL One of the best papers I have read this year. Congratulations to authors!

[NIDDK @NIDDKgov]

In an NIDDK study conducted with international support, researchers invented a light-activated psoriasis drug to selectively target skin lesions in a mouse model of psoriasis, reducing the likelihood of undesirable side effects. https://t.co/3l4tEewP4H @ACSPublications

[NIDDK @NIDDKgov]

Researchers from @SLU_Official and NIDDK discovered activating a mitochondrial adenosine receptor (A3AR) protects rodent neurons from chemotherapy-induced neurotoxicity (CIPN), a common cause of nerve pain in cancer patients https://t.co/ZzfxaFBsdJ @SfNJournals

[NIDDK @NIDDKgov]

NIDDK research out now in @nchembio: Selective Bioorthogonal Probe for N-Glycan Hybrid Structures. https://t.co/syamDRqd5h

[Kenneth Jacobson @KAJacobson]

@NIDDKgov @JMedChem @ACSPublications Collaboration with John McCorvy at Medical College of Wisconsin and other labs

[NIDDK @NIDDKgov]

Serotonin, a molecule known for its regulation of neural activity and mood, can also cause inflammation. With reengineered molecules, the researchers blocked an inflammatory serotonin pathway at specific receptors outside the brain.